Johnson & Johnson May See Earnings Growth Despite OTC Drug Recalls

Published July 20, 2010

Johnson & Johnson May See Earnings Growth Despite OTC Drug Recalls
Pharmaceutical giant Johnson & Johnson is scheduled to report financial results for the second quarter before the market opens on Tuesday, with analysts expecting the company to report a near 5% increase in profit from the year-ago quarter despite product recalls at its OTC drug unit.
Read more on RTT News

Ecstasy ‘may help trauma sufferers’
THE drug Ecstasy can help the tortured victims of post traumatic stress overcome their demons, American research has shown.
Read more on News Mail

Only 51% of HIV-exposed infants received minimal dose of prevention drug nevirapine: Study
In the ongoing battle to prevent mother-to-child transmission of human immunodeficiency virus (HIV), not all weapons are being used: Only about half of HIV-exposed infants in some African countries received a minimal dose of the prevention drug nevirapine, say researchers at the University of Alabama at Birmingham.
Read more on News-Medical-Net